November 2013 | Oncology & Biotech News

Hot Flash Treatments That Help Women Fail to Benefit Androgen-Deprived Men

December 20, 2013

Men who experience hot flashes because they are undergoing androgen-deprivation therapy for prostate cancer are not significantly helped by two treatments that alleviate that symptom in menopausal women, the results of a study show.

Stemline Therapeutics Targets Capacity of Tumors to Adapt and Proliferate

December 17, 2013

The investigational cancer medications being developed by Stemline Therapeutics attack only a tiny percentage of all tumor cells. But those few cells-the stem cells that resist most treatment and drive tumor growth-may just be the most important ones.

Burgeoning Field of Interventional Oncology Is Poised for Takeoff: A Q&A With Dan Brown, MD

December 05, 2013

Interventional oncology is an emerging field in cancer care that is intended to complement existing treatment modalities. We sat down with Dan Brown, MD, the new chief of Interventional Oncology at Vanderbilt University Medical Center, to discuss the burgeoning field and its potential effect on cancer care moving forward.

Nab-Paclitaxel Boosts Survival in Pancreatic Cancer

December 04, 2013

The addition of albumin-bound paclitaxel (nab-paclitaxel; Abraxane) to standard treatment with gemcitabine significantly lengthens survival in patients with metastatic pancreatic cancer, researchers report.

Ramucirumab Improves Survival in Advanced Gastric Cancer

December 02, 2013

Ramucirumab, a monoclonal antibody that targets VEGFR-2, significantly prolonged survival in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following progression on first-line therapy, according to results from the phase III REGARD study published in The Lancet.

Quest Diagnostics Launches New BRCA 1/2 Test

December 02, 2013

Quest Diagnostics, a business founded 46 years ago in a medical resident's two-room apartment, has parlayed the exponential subsequent growth in medical testing into an operation worth $8.5 billion.